Guo Zhi-Chen, Jumatai Sakendeke, Jing Si-Li, Hu Lu-Lu, Jia Xin-Yu, Gong Zhong-Cheng
Oncological Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830054, P.R. China.
Department of Ophthalmology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830054, P.R. China.
Oncol Lett. 2021 Mar;21(3):189. doi: 10.3892/ol.2021.12450. Epub 2021 Jan 6.
The present study aimed to detect the immunoexpression and clinical significance of () in the tumor microenvironment (TME) of oral squamous cell carcinoma (OSCC). The immunoexpression of in OSCC tissues was detected via immunohistochemistry (IHC) after was infected into the TME of OSCC. To identify the differentially expressed genes in the carcinogenesis and progression of OSCC with infection, microarray datasets (GSE87539 and GSE138206) were downloaded from the Gene Expression Omnibus database. The immunoexpression levels of C-X-C motif chemokine ligand 2 (CXCL2) and tumor-associated neutrophils (TANs) were also evaluated via IHC, and the immunoexpression levels of all three clinical variables were analyzed using χ or Fisher's exact tests. The survival rates were calculated using the Kaplan-Meier method and the survival curves were compared using log-rank tests. Predominantly strong immunoexpression of was identified in OSCC samples. CXCL2 was considered to be a differential gene in the two datasets. Immunoexpression of was positively associated with CXCL2 and TANs expression. Furthermore, was associated with survival status (P<0.001) and differentiation (P<0.001). CXCL2 was associated with age (P=0.038) and survival status (P=0.003), while TANs were associated with T stage (P=0.015) and clinical stage (P=0.002). These clinical variables were considered to be independent risk factors for the poor prognosis of patients with OSCC. Collectively, the results suggested that the immunoexpression of may be positively associated with CXCL2 and TANs. In addition, the strong immunoexpression levels of , CXCL2 and TANs may be associated with a poor prognosis in patients with OSCC.
本研究旨在检测（）在口腔鳞状细胞癌（OSCC）肿瘤微环境（TME）中的免疫表达及其临床意义。在将（）感染到OSCC的TME后，通过免疫组织化学（IHC）检测其在OSCC组织中的免疫表达。为了鉴定感染（）后OSCC发生发展过程中差异表达的基因，从基因表达综合数据库下载了微阵列数据集（GSE87539和GSE138206）。还通过IHC评估了C-X-C基序趋化因子配体2（CXCL2）和肿瘤相关中性粒细胞（TANs）的免疫表达水平，并使用χ检验或Fisher精确检验分析了所有三个临床变量的免疫表达水平。采用Kaplan-Meier法计算生存率，并使用对数秩检验比较生存曲线。在OSCC样本中主要鉴定出（）的强免疫表达。CXCL2被认为是两个数据集中的差异基因。（）的免疫表达与CXCL2和TANs的表达呈正相关。此外，（）与生存状态（P<0.001）和分化（P<0.001）相关。CXCL2与年龄（P=0.038）和生存状态（P=0.003）相关，而TANs与T分期（P=0.015）和临床分期（P=0.002）相关。这些临床变量被认为是OSCC患者预后不良的独立危险因素。总体而言，结果表明（）的免疫表达可能与CXCL2和TANs呈正相关。此外，（）、CXCL2和TANs的强免疫表达水平可能与OSCC患者的不良预后相关。
